Cavaliere Robert, Lopes Maria Beatriz S, Schiff David
Neuro-oncology Center, University of Virginia, Box 800432, Charlottesville, VA 22908, USA.
Lancet Neurol. 2005 Nov;4(11):760-70. doi: 10.1016/S1474-4422(05)70222-2.
Low-grade gliomas (LGG) are not benign neoplasms. Patients with LGG eventually die as a consequence of this disease. Although the survival of patients with LGG is better than that of patients with higher-grade tumours, many of the treatments can produce or contribute to chronic impairment, particularly radiotherapy. Chemotherapy has emerged as a promising therapy, although definitive findings are awaited. Breakthroughs in molecular biology have improved our understanding of tumours and have led to the development of novel treatments and better prognoses. Ongoing clinical trials will help to elucidate the optimum management of patients with LGG.
低级别胶质瘤(LGG)并非良性肿瘤。LGG患者最终会因这种疾病而死亡。尽管LGG患者的生存率高于高级别肿瘤患者,但许多治疗方法会导致或加重慢性损伤,尤其是放疗。化疗已成为一种有前景的治疗方法,不过仍有待明确的研究结果。分子生物学的突破增进了我们对肿瘤的理解,并推动了新治疗方法的开发和更好预后的实现。正在进行的临床试验将有助于阐明LGG患者的最佳治疗方案。